General Information of Drug (ID: DMXD1IN)

Drug Name
CX-5011 Drug Info
Synonyms
1333382-30-1; UNII-2F5JG09KS6; CX-5011; 2F5JG09KS6; sodium 5-(3-ethynylphenylamino)pyrimido[4,5-c]quinoline-8-carboxylate; AOB1816; AKOS027422619; Pyrimido(4,5-C)quinoline-8-carboxylic acid, 5-((3-ethynylphenyl)amino)-, sodium salt (1:1)
Indication
Disease Entry ICD 11 Status REF
Solid tumour/cancer 2A00-2F9Z Investigative [1]
Cross-matching ID
PubChem CID
70702100
CAS Number
CAS 1333382-30-1
TTD Drug ID
DMXD1IN

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Clinical Trial Drug(s)
Discontinued Drug(s)
Investigative Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
CX-4945 DMWE7B9 Coronavirus infection 1D92 Phase 2 [2]
BALANOL DMDLN9E N. A. N. A. Terminated [3]
EMODIN DMAEDQG Coronavirus Disease 2019 (COVID-19) 1D6Y Terminated [4]
4-[(3,5-diamino-1H-pyrazol-4-yl)diazenyl]phenol DMSKJ1X Discovery agent N.A. Investigative [5]
4,5,6,7-tetrabromo-1H-benzo[d][1,2,3]triazole DMN9YOB Discovery agent N.A. Investigative [4]
ELLAGIC ACID DMX8BS5 Discovery agent N.A. Investigative [4]
APIGENIN DMI3491 Discovery agent N.A. Investigative [4]
PMID24900749C1a DMZPUSO Discovery agent N.A. Investigative [6]
AdoC(Dpr)2AlaArg6 DM2TWSZ Discovery agent N.A. Investigative [7]
PMID22115617C2c DMX5UKA Discovery agent N.A. Investigative [8]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Casein kinase II alpha (CSNK2A1) TTER6YH CSK21_HUMAN Inhibitor [1]

References

1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1549).
2 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
3 Synthesis and protein kinase C inhibitory activities of acyclic balanol analogs that are highly selective for protein kinase C over protein kinase A. J Med Chem. 1996 Dec 20;39(26):5215-27.
4 Structural insight into human CK2alpha in complex with the potent inhibitor ellagic acid. Bioorg Med Chem Lett. 2009 Jun 1;19(11):2920-3.
5 4-arylazo-3,5-diamino-1H-pyrazole CDK inhibitors: SAR study, crystal structure in complex with CDK2, selectivity, and cellular effects. J Med Chem. 2006 Nov 2;49(22):6500-9.
6 Structure and Property Based Design of Pyrazolo[1,5-a]pyrimidine Inhibitors of CK2 Kinase with Activity in Vivo. ACS Med Chem Lett. 2013 Jul 3;4(8):800-5.
7 Adenosine-5'-carboxylic acid peptidyl derivatives as inhibitors of protein kinases. Bioorg Med Chem Lett. 1999 May 17;9(10):1447-52.
8 CK2alpha and CK2alpha' subunits differ in their sensitivity to 4,5,6,7-tetrabromo- and 4,5,6,7-tetraiodo-1H-benzimidazole derivatives. Eur J Med Chem. 2012 Jan;47(1):345-50.